期刊文献+

The future of pediatric hepatocellular carcinoma:a combination of surgical,locoregional,and targeted therapy

原文传递
导出
摘要 Despite hepatocellular carcinoma’s position as the second most common pediatric liver tumor,it is a rare tumor in children warranting international collaboration to improve outcomes.Few cases diagnosed in earlier stages,when confined to the liver and responding to systemic treatment or with resectable metastases,may be cured by complete resection and/or orthotopic transplantation.Complete resection is the only chance for cure;therefore,all attempts should be made to make these options available.Despite modest progress in locoregional treatments,these serve in most cases as palliative treatment or as a bridge to definitive treatment at best.Currently used systemic treatments have response rates below 50%.Five-year survival in advanced stages is below 30%.The international Paediatric Hepatic International Tumour Trial trial is evaluating novel systemic treatments in pediatric hepatocellular carcinoma.Patients suffering from these tumors likely benefit from targeted treatment based on molecular aberrations corresponding with tumor subtype.
出处 《Hepatoma Research》 2021年第1期894-900,共7页 肝癌研究(英文版)
  • 相关文献

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部